Article
Comparative Real Life Egyptian Experience of the Combination of Sofosbuvir Plus Daclatasvir or Simeprevir for 12 Weeks in Naïve Cirrhotic Patients Infected with HCV Genotype 4.
Current drug safety - 1 Jan 2023
Ahmed Sayed, Hassan Essam, Gomaa Ahmed, Esamat Gamal, Ramadan Ahmed, Ahmed Manar, Elsayed Aya, A Wahsh Engy
Abstract excerpt
BACKGROUND: Chronic infection with HCV is progressive worldwide health problem and the core reason for liver cirrhosis, portal hypertension, or hepatocellular carcinoma. HCV-G4 represents the most common threat to transplantation of the liver in Egypt. New interferon-free regimens have been started consuming direct-acting antiviral oral tablets for HCV cure. OBJECTIVES: In the current study, comparing the safety...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.